Novartis gets European approval for psoriasis drug Cosentyx

Credit: REUTERS/Arnd Wiegmann

Novartis has received European Union approval for its Cosentyx drug to be a standard treatment for psoriasis in children, the company said on Monday.

ZURICH, Aug 3 (Reuters) - Novartis NOVN.S has received European Union approval for its Cosentyx drug to be a standard treatment for psoriasis in children, the company said on Monday.

The decision follows studies which showed the drug gave fast and strong skin clearance for children with the condition, Novartis said.

(Reporting by John Revill; Editing by Jacqueline Wong)

((John.Revill@thomsonreuters.com; +41 58306 7022; Reuters Messaging: john.revill.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NOVN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More